Merger Momentum: Tracking the Margin Expansion in a Consolidated Aster DM
healthcare · merger consolidation · EBITDA margin
healthcare · merger consolidation · EBITDA margin

GLENMARK · Q2 FY27 · pharma

margin recovery · US generics · India formulations

healthcare · earnings · guidance

custom synthesis · margin expansion · EBITDA

speciality chemicals · api intermediates · margin compression

USFDA · ANDA approval · Venetoclax

EBITDA margin · Consumer Healthcare · tax headwind

EBITDA upside · consumer weakness · chronic expansion

pharma · exceptional items · organon acquisition

fmcg · brand divestiture · exceptional gain

pharmaceuticals · margin expansion · us generics growth

US generics · EBITDA margin · biosimilars

margin compression · freight impact · regulated markets

margin compression · emerging markets strength · freight impact

diagnostics · pathology · exceptional item

cdmo · margin expansion · operating leverage

pharmaceuticals · cdmo exports · margin expansion

generic pharmaceuticals · anda pipeline · margin expansion

JB integration · cost synergies · PAT erosion

diagnostics · revenue growth · margin expansion

healthcare · hospital expansion · margin pressure

pharma · turnaround · Q2 FY27

consumer healthcare · pharma · margin expansion

FDC · buyback · tender offer

pharma earnings · revenue growth · minipress discontinuation

CDMO · peptide-expansion · FDA-approval

export growth · margin trajectory · Gennova integration
